文献速递哮喘

加巴喷丁类药物与哮喘急性发作风险:全国性回顾性队列研究

Gabapentinoids and risk for asthma exacerbations: a nationwide retrospective cohort study.
PubMed 文献 · Thorax · 2026-01-15

该研究利用美国全国行政索赔数据库,构建有神经病理性或慢性疼痛且患哮喘的加巴喷丁类新用户与三环类抗抑郁药(TCA)或5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)新用户两个活性对照队列,采用重叠倾向评分加权控制混杂,以加权Cox模型评估需全身糖皮质激素的哮喘急性发作(主要结局)和需住院的哮喘(次要结局)。结果显示,与TCA或SNRI相比,加巴喷丁类使用与主要结局风险升高相关;与TCA相比次要结局风险亦升高,与SNRI相比次要结局差异无统计学意义。

要点

  • 与TCA相比,加巴喷丁类主要结局HR 1.46(95%CI 1.34–1.60),次要结局HR 2.02(1.11–3.68)。
  • 与SNRI相比,加巴喷丁类主要结局HR 1.24(1.19–1.30),次要结局HR 1.24(0.94–1.63)无统计学意义。
  • 哮喘患者用加巴喷丁类治神经病理性或慢性疼痛需谨慎。

核心结论

  • 与TCA或SNRI相比,加巴喷丁类使用与哮喘急性发作风险升高相关。

研究设计与样本

  • 全国性回顾性活性对照新用户队列研究,使用全国行政索赔数据库。
  • 采用重叠倾向评分加权控制混杂,加权Cox比例风险模型评估结局。

主要发现

  • TCA队列主要结局发生率59.4 vs 33.7/100人年,HR 1.46(95%CI 1.34–1.60)。
  • TCA队列次要结局发生率0.91 vs 0.42/100人年,HR 2.02(95%CI 1.11–3.68)。
  • SNRI队列主要结局发生率63.5 vs 42.8/100人年,HR 1.24(95%CI 1.19–1.30)。
  • SNRI队列次要结局发生率0.93 vs 0.68/100人年,HR 1.24(95%CI 0.94–1.63),差异无统计学意义。

临床怎么用

  • 哮喘患者管理神经病理性或慢性疼痛时,使用加巴喷丁类应谨慎并权衡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite warnings from the US Food and Drug Administration about respiratory adverse events associated with gabapentinoids, direct evidence of their risk in patients with asthma is lacking. METHODS: Using a national administrative claims database, we prepared two active comparators-new user cohorts of patients with a history of neuropathic or chronic pain and asthma-initiating gabapentinoids and comparator drugs (tricyclic antidepressants (TCAs) or serotonin norepinephrine reuptake inhibitors (SNRIs)). Overlap propensity score weighting was used to control for potential confounders. The initial occurrence of asthma exacerbation requiring systemic corticosteroids (primary) or those requiring hospitalisation for asthma (secondary) was assessed using a weighted Cox proportional hazards model. FINDINGS: In the TCAs cohort (171 393 gabapentinoids users and 5916 TCAs users), gabapentinoids use was associated with a higher incidence of primary (59.4 vs 33.7 per 100 person-years; HR 1.46, 95% CI 1.34 to 1.60) and secondary outcomes (0.91 vs 0.42 per 100 person-years; 2.02, 1.11 to 3.68). In the SNRIs cohort (189 055 gabapentinoids users and 19 800 SNRIs users), using gabapentinoids was also associated with a higher incidence of primary outcome (63.5 vs 42.8 per 100 person-years; HR 1.24, 1.19 to 1.30). However, the difference in the secondary outcome did not reach statistical significance (0.93 vs 0.68 per 100 person-years; 1.24, 0.94 to 1.63). INTERPRETATION: Gabapentinoids were associated with an increased risk of asthma exacerbations compared with TCAs or SNRIs. Managing neuropathic or chronic pain in patients with asthma using gabapentinoids should be approached with caution.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Kimura, Jo, Inoue, et al. Gabapentinoids and risk for asthma exacerbations: a nationwide retrospective cohort study. Thorax. 2026. PMID: 40850791. doi:10.1136/thorax-2025-223240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。